​

Allurion Stock (NYSE:ALUR)

RevenueOwnershipFinancialsChartTranscripts
Allurion by TradingView

Previous Close

$0.75

52W Range

$0.23 - $3.42

50D Avg

$0.80

200D Avg

$1.65

Market Cap

$6.03M

Avg Vol (3M)

$2.68M

Beta

-0.25

Div Yield

-

ALUR Company Profile

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

134

IPO Date

Mar 29, 2021

Website

ALUR Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24
ITALY$1.84M-
All Other Countries$11.23M$24.04M
SPAIN$2.15M$4.01M
FRANCE-$2.49M

Fiscal year ends in Dec 24 | Currency in USD

ALUR Financial Summary

Dec 24Dec 23Dec 22
Revenue$32.11M$53.47M$64.21M
Operating Income$-50.20M$-79.08M$-32.01M
Net Income$-26.15M$-82.30M$-37.74M
EBITDA$-50.20M$-69.03M$-32.28M
Basic EPS$-0.01$-2.31$-1.40
Diluted EPS$-0.01$-2.31$-1.40

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 12, 25 | 8:30 AM
Q2 25Aug 13, 25 | 8:30 AM
Q1 25May 14, 25 | 8:30 AM

Peer Comparison

TickerCompany
LFWDLifeward Ltd.
COCHEnvoy Medical, Inc.
ERNAErnexa Therapeutics Inc.
ADAPAdaptimmune Therapeutics plc
PRPHProPhase Labs, Inc.
AEMDAethlon Medical, Inc.
CODXCo-Diagnostics, Inc.
VVOSVivos Therapeutics, Inc.
NVNOenVVeno Medical Corporation
XAIRBeyond Air, Inc.